Bio Rhythm: A Comprehensive Look at Worldwide Innovation

BIO RHYTHM Biotechnology is constantly changing. The release of a new patent, an adjustment to a government policy, or a private financial boost can catapult an obscure firm into the worldwide arena that pushes science forward. Below is a look at the current state Comprehensive Look at Worldwide Innovation Centers by Region, Country, and Investment of monetary investments and the innovation they stimulate around the globe. The Top Regions in Biotechnology Applications Number of biotechnology firms: 25 35 45 BRIC EUROPEAN UNION JAPAN US Top 10 regions in biotechnology applications San Jose-San Francisco-Oakland U.S Total patents: 1510 Worldwide share: 5.5% 6 San Diego-Carlsbad-San Marcos U.S Total patents: 782 Worldwide share: 2.9% O Los Angeles-Long Beach-Riverside U.S Total patents: 613 Worldwide share: 2.2% Boston-Worcester-Manchester U.S Total patents: 1422 Worldwide share: 5.2% 8 Philadelphia-Camden-Vineland U.S Total patents: 587 Worldwide share: 2.2% New York-Newark U.S Total patents: 1090 Worldwide share: 4% US 40.6 EUROPEAN UNION 25.1 Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom Washington-Baltimore-N.Virginia U.S Total patents: 811 Worldwide share: 3% O Nordrhein-VWesfalen Germany Total patents: 506 Worldwide share: 1.9% 6 Tokyo Japan Total patents: 792 Worldwide share: 2.9% 10 Region Hovedstaden (Copenhagen Capital Region), Denmark Total patents: 454 Worldwide share: 1.7% JAPAN 17.0 BRIC 2.7 Russia, India, China Brazil Map does not reflect all countries biotech applications. Investment Patent applications 12,000 $6 BIL I Total Patent Applications $5.5 BIL 10,000 – E$5 BIL Total Venture Capital Investments in Life Sciences, Million PPP ($) 2007* 78 percent of biotech companies around the world have less than 50 employees, and 9 percent of biotech companies have between 50 and 100 employees. 8,000 – E$4 BIL * Venture Capital is limited to investment in seed, start-up, early development, and expansion stages. 6,000 - E$3 BIL 4,000 - F$2 BIL 3,720 2,000 - $293.6 MIL E$1 BIL $0 United Kingdom South Korea USA Japan Germany France Netherlands Australia Denmark Italy China* Sweden Switzerland Belgium Spain Finland Portugal *China's Venture Capital is not available. INNOVATION A 2011 GE Global Innovation Barometer Report examined innovation percentages by country in their independent survey of 1,000 business executives in 12 countries. USA Germany Japan China Korea India Sweden UK Israel France Current Biotech Projects in Clinical Phases by Country RISING STAR In 2010, China spent $1 billion on biotech investments. In the next five years, the most populous country in the world plans to spend $308.5 billion on sciences, focusing largely on biotech. China is positioning itself to be a leader in biotech innovation in the 25 50 75 100 125 150 175 200 225 250 275 300 Australia China South Korea Japan Taiwan decades to come. Singapore India Only countries with recent growth and investment in biotech are included for comparison. Growth in biotech can occur and be nurtured anywhere the government and private sectors realize its potential. For larger economies, biotech continues to be an asset. For smaller economies, biotech provides an opportunity to enhance not only science but quality of life for citizens and, through their innovation, the entire world. SOURCES: All data appears from the year most recent statistics were available (2004-2011) EY.COM GE.COM OECD.COM NOVUMED.COM UUU ÚUù assay depot UUU